Johnson & Johnson: Inflammatory Bowel Diseases trials

The registry lists 15 Inflammatory Bowel Diseases studies with Johnson & Johnson as lead sponsor. 7 are open to participants now and 5 have results posted.

Phase 3 5Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian SettingNot yet recruitingNCT07851207
• A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel DiseaseRecruitingNCT07822529
• A Study to Assess Real-world Outcomes for Long-Term Use of GuselkumabRecruitingNCT07532213
• A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in KoreaRecruitingNCT07520747
• A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)RecruitingNCT07242248
• A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in GermanyRecruitingNCT07102368
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05923073Phase 3
• An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel DiseaseTerminatedNCT02566889Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT02407236Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)CompletedNCT01369355Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)CompletedNCT01369342Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)CompletedNCT01369329Phase 3Results posted
• Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory DiseasesCompletedNCT03606499
• Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and PsoriasisCompletedNCT00658827
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseActive, not recruitingNCT00606346